EDEUS, a Real-Life Study on the Users of Phosphodiesterase Type 5 Inhibitors: Prevalence, Perceptions, and Health Care-Seeking Behavior Among European Men With a Focus on 2nd-Generation Avanafil
Open Access
- 21 December 2017
- journal article
- research article
- Published by Oxford University Press (OUP) in Sexual Medicine
- Vol. 6 (1) , 15-23
Abstract
Introduction: Erectile dysfunction (ED) is a multidimensional disorder with an estimated prevalence of 1% to 10% in men younger than 40 years and up to 100% in men in their 70s and 80s.Aim: To evaluate the real-life characteristics and unmet needs of men with ED, its impact on well-being, and treatment rates across Europe.Methods: Adult men in Belgium, France, Germany, Italy, Poland, Portugal, and Spain were invited to participate in the survey. Men who did not use at least a drug for sexual health in the past 3 months, had cancer or spinal cord injuries, and/or underwent non–nerve-sparing radical prostatectomy were excluded.Main Outcome Measures: The 15-item International Index of Erectile Function (IIEF-15) with study-specific, self-constructed questions was used.Results: Overall, 940 subjects (age = 46.2 ± 13.4 years) were considered. Subjects (n = 778) using on-demand phosphodiesterase type 5 inhibitors (PDE5is) were designated “performers” (60%) without a formal ED diagnosis or “patients” with a medical diagnosis. Patients were older than performers, with more self-reported comorbidities; patients used a higher PDE5i dosage and purchased it from official pharmacies more often than performers did. Of avanafil users (n = 39), no differences in total IIEF or subdomain scores were observed after adjusting for confounders. However, avanafil users less often declared its use without an ED diagnosis and a physician prescription. Overall, the latter condition was associated with higher PDE5i-related satisfaction.Conclusion: The survey shows 2 different attitudes toward ED and PDE5i use: for recreational use and without a medical prescription or with a formal diagnosis and medical prescription. Avanafil, a 2nd-generation PDE5i with a good balance between efficacy and tolerability profile, is more frequently prescribed by doctors than self-prescribed compared with other PDE5is. Because the major challenge is to decrease the high dropout of 1st-generation PDE5is, further studies will be needed to clarify this topic.Keywords
This publication has 47 references indexed in Scilit:
- Prediction of Cardiovascular Events and All-Cause Mortality With Erectile DysfunctionCirculation: Cardiovascular Quality and Outcomes, 2013
- Help‐Seeking Interval in Erectile Dysfunction: Analysis of Attitudes, Beliefs, and Factors Affecting Treatment‐Seeking Interval in Turkish Men With Previously Untreated Erectile DysfunctionJournal of Andrology, 2012
- How to Evaluate the Efficacy of the Phosphodiesterase Type 5 InhibitorsThe Journal of Sexual Medicine, 2012
- Recreational Use of Phosphodiesterase Type 5 Inhibitors by Healthy Young MenThe Journal of Sexual Medicine, 2010
- Impairment of Couple Relationship in Male Patients with Sexual Dysfunction is Associated with Overt HypogonadismThe Journal of Sexual Medicine, 2009
- Recreational Use of PDE5 Inhibitors by Young Healthy Men: Recognizing This Issue Among Medical StudentsThe Journal of Sexual Medicine, 2008
- Psychosocial interventions for erectile dysfunctionCochrane Database of Systematic Reviews, 2007
- Subclinical Erectile Dysfunction: Proposal for a Novel Taxonomic Category in Sexual MedicineThe Journal of Sexual Medicine, 2006
- Male sexuality and regulation of emotions: a study on the association between alexithymia and erectile dysfunction (ED)International Journal Of Impotence Research, 2005
- The Prevalence of Bother, Acceptance, and Need for Help in Men with Erectile DysfunctionThe Journal of Sexual Medicine, 2005